ClinicalImpact™ Melanoma: Expert Guidance and Resources to Optimize Care Along the Treatment Continuum

Download this slideset to gain key insights on adjuvant therapy and best practice management of high-risk melanoma through the use of targeted therapy and immunotherapy

Ahmad Tarhini, MD, PhD Released: November 3, 2020

Download this slideset to gain key insights into current therapeutic strategies in advanced melanoma, including optimal approaches for managing CNS metastases.

Michael A. Davies, MD, PhD Released: November 3, 2020

Download this short summary slideset of key takeaways from a live CCO Webinar focused on current management of patients with high-risk resectable or metastatic melanoma.

Michael A. Davies, MD, PhD Ahmad Tarhini, MD, PhD Released: November 6, 2020

How do you choose among approved adjuvant therapies for BRAF V600E/K high-risk melanoma? Read my thoughts on factors to consider when selecting adjuvant targeted therapy for your patients.

Douglas B. Johnson, MD, MSCI Released: October 19, 2020

Here are my thoughts on key considerations when selecting frontline therapy for patients with metastatic melanoma, including when targeted therapy may be preferred over immunotherapy, factors that affect the selection of single-agent or combination immunotherapy, and when to discontinue immunotherapy.

Allison Betof Warner, MD, PhD Released: February 17, 2021